Steven King

Insider Reports History

Entity
Individual
Signature
/s/ Paul Lytle, as attorney-in-fact for Steven King
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Steven King:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Oncotelic Therapeutics, Inc. Director Stock Options 500K Sep 3, 2021 Direct
Mosaic ImmunoEngineering Inc. President and CEO, Director, 10%+ Owner Convertible Note $20K Feb 18, 2022 Direct

Insider Reports Filed by Steven King

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CPMV Mosaic ImmunoEngineering Inc. Feb 18, 2022 1 $20K 4 Feb 22, 2022 President and CEO, Director, 10%+ Owner
OTLC Oncotelic Therapeutics, Inc. Sep 3, 2021 1 $0 4 Sep 8, 2021 Director
OTLC Oncotelic Therapeutics, Inc. Mar 31, 2021 3 $0 4 Jul 16, 2021 Director